Custom Search

Sunday, October 7, 2012

Anti HIV drug nelfinavir exhibits anticancer activity against HER2 positive breast cancer cells

Anti-cancer activity of an anti retroviral drug:

Nelfinavir is a drug used in treatment of HIV infection to lower the HIV viral load. It is an enzyme inhibitor drug which inhibit an enzyme which breakdown protein from human cells in to in to small units, which are then used for formation of HIV viron capsule and rest of proteins responsible for activity of HIV. The enzyme is known as retroviral aspartyl protease, and the drug is known as protease inhibitor.

Simillar approach is also adapted in treatment of Hepatitis C and drugs used for the purpose are Boceprevir and Telaprevir.

The drug Nelfinavir is also being studied extensively for its activity against various cancer cell invitro, and it is found that it can facilitate killing of cancer cell (Apoptosis) when combined with radiation therapy.

Breast cancer is one of big reason for loses of lives in world wide of which breast cancer which is positive of Human Epidermal Growth Factor Receptor 2 is most difficult to treat and its progression is rapid.

Researchers at Johns Hopkins School of Medicine have studied effect of Nelfinavir on HER2 positive breast cancer in vitro over which they found satisfactory and later on confirmed the same in mice model, the concentration of drug required to bring about anticancer activity is almost similar to the existing dosage required for its antiretroviral activity.

This finding can be explored to develop more effective drug for HER2 positive breast cancer by developing analog drugs similar to Nelfinavir.

Other protease inhibitor drugs are ritonavir, indinavir, amprenavir,saquinavir, nelfinavir.

No comments:

Posted by: Martin

How to sucessfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.


1.You should write your Email ID in the box provided and push the subscribe butten


2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Cheke our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.




Enter your email address get our articles by email whenever this website is updated





Delivered by FeedBurner



Join the list of our readers from Universities ,Research and Development centers Pharmaceutical Companies from all over the world.











Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: editor@pharmacistspharmajournal.org Website: http://pharmacistspharmajournal.org/
Copyright © 2008-2015 all rights reserve www.pharmacistspharmajournal.org